Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight ...

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...